Skin Biology Receives US Patent for Non-toxic Skin Cancer Therapy With Copper Peptides

Describes method to biologically remove human basal skin cancers and melanomas in horses

BELLEVUE, Wash.--()--Skin Biology Inc. today announced that they have received US patent 9,586,989 for "Non-toxic skin cancer therapy with copper peptides". The patent describes a method to biologically remove basal skin cancers in humans and melanomas in horses.

Skin Cancer is Most Common Cancer in U.S.

According to, more than 5.4 million cases of skin cancer are treated in more than 3.3 million people in the United States each year. Over the past three decades, more people have had skin cancer than all other cancers combined. One in five Americans will develop skin cancer in the course of a lifetime.

Copper Peptides’ Role in Skin Cancer Treatment

The medical community continuously researches ways to both improve the effectiveness of cancer treatment therapies and to reduce their negative impact on patients. For example, current skin cancer therapies -- such as surgery and toxic anti-cancer drugs -- often leave extensive scarring.

Certain mild non-toxic copper peptides inhibit cancers by: inducing cell differentiation; suppressing cancer metastasis genes; resetting programmed cell death systems in human cancer lines, such as neuroblastoma, leukemia, and breast; and altering the expression of 85 genes in a manner that inhibits cell growth.

“Most current therapies to treat disease target only one biochemical reaction or pathway,” said Pickart. "Our mission is to find ways to utilize copper peptides to reset hundreds of genes to regenerate and protect at-risk tissues and organs."

Skin Biology Founder: Previously Founder of ProCyte Corp.

Skin Biology's founder Loren Pickart, Ph.D. had previously discovered the human regenerative and protective copper peptide GHK-Cu. Pickart was also founder of ProCyte Corporation, a biotechnology company that went public and later merged with PhotoMedex.

About Skin Biology

Skin Biology is biotechnology company which sells cosmetic skin products to support its research on the actions of regenerative and protective copper peptides. Headquarters is 4122 Factoria Blvd SE, Suite 200, Bellevue, WA. Please visit


Skin Biology
Dr. Loren Pickart, 425-644-0160

Release Summary

Skin Biology, Inc. received US patent 9,586,989 for "Non-toxic skin cancer therapy with copper peptides."


Skin Biology
Dr. Loren Pickart, 425-644-0160